In Q2, Johnson & Johnson JNJ saw a decline in both earnings and sales. Earnings decreased by 75.25% to $5.80 billion, and sales dropped by 11.38% to $18.34 billion. In Q1, Johnson & Johnson earned $23.42 billion and total sales reached $20.69 billion.
What Is ROCE?
Changes in earnings and sales indicate shifts in Johnson & Johnson’s Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed in a business. Generally, a higher ROCE suggests successful growth in a company and is a sign of higher earnings per share for shareholders in the future. In Q2, Johnson & Johnson posted a ROCE of 1.86%.
It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.
ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Johnson & Johnson is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will lead to higher returns and earnings per share growth.
For Johnson & Johnson, the return on capital employed ratio shows the number of assets can actually help the company achieve higher returns, an important note investors will take into account when gauging the payoff from long-term financing strategies.
Q2 Earnings
Johnson & Johnson reported Q2 earnings per share at $1.67/share against analyst predictions of $1.48/share.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.